Mitsui Ventures 三井ベンチャーズ(MVC、MCVP) ベンチャーキャピタル ベンチャー 三井物産 起業

NEWS 2007

[02/13/2007]

Biolex Therapeutics Featured At Next Generation Antibody Panel At BIO CEO & Investor Conference

PITTSBORO, NORTH CAROLINA, February 13, 2007 - Biolex Therapeutics today announced that its technology for optimizing monoclonal antibodies will be featured at the “Next Generation Antibodies and Antibody Technologies” session at the 9th Annual BIO CEO & Investor Conference. David Spencer, Ph.D., Biolex’s Chief Operating Officer and Senior Vice President, Research and Development, will highlight the ability of the Company’s LEX SystemSM to increase the efficacy and potency of monoclonal antibodies. The antibody session will take place at 9:00 a.m. EST on Wednesday, February 14th at the Waldorf Astoria in New York City.

Monoclonal antibodies comprise the fastest growing class of protein therapeutics and are currently being used and developed primarily to treat cancers, autoimmune diseases, infectious diseases and inflammatory diseases. Recently, Biolex announced results published in Nature Biotechnology demonstrating the ability of its proprietary LEX System to produce monoclonal antibodies that have enhanced potency and efficacy. The publication also describes the LEX System’s ability to produce antibodies with homogeneous glycosylation structures, an additional major advantage of the LEX System compared to expression systems commonly used today, and key to reducing production risks, regulatory risks and costs.

“Biolex has successfully produced antibodies with optimized glycosylation in multiple protein candidates held by our corporate partners and in one of our own product candidates,” said David Spencer, Ph.D., Biolex Chief Operating Officer and Senior Vice President, Research and Development. “The ability of the LEX System to produce antibodies with greater functionality is obviously a major benefit. Moreover, controlling glycosylation and achieving consistent production throughout scale-up resolves a significant challenge facing the biopharmaceutical industry.”

About Biolex Therapeutics

Biolex Therapeutics is developing and commercializing therapeutic proteins based on the LEX SystemSM, its patented expression system that enables the production of hard-to-make proteins and the optimization of monoclonal antibodies.

The Company is developing a proprietary pipeline of products that rely upon known mechanisms of action to provide a reduced risk profile while targeting large, proven pharmaceutical markets. Biolex's lead clinical candidate, Locteron? is being developed as a best-in-class controlled-release interferon alfa for the treatment of hepatitis C.

The Company's second product candidate, BLX-155, is a direct-acting thrombolytic, designed to break up clots in certain diseases such as acute peripheral arterial disease, deep vein thrombosis and catheter occlusion. In addition, the unique capabilities of the LEX System have led to collaborations with Centocor, Medarex and other leading pharmaceutical/biotech companies.

Biolex is a venture capital-backed company located in the Research Triangle region of North Carolina, United States. For additional information, please visit Biolex's web site at http://www.biolex.com

http://www.biolex.com/

Contacts:

Media: Michelle Linn, Linnden Communications, 508-419-1555, linnmich@comcast.net
Investors: Dale Sander, Chief Financial Officer, 858-663-6993, dsander@biolex.com